EP

Epics Therapeutics

2 known investors

epicstherapeutics.com ↗

EPICS Therapeutics develops RNA epigenetics-based cancer treatments, focusing on METTL3 inhibitors for cancers including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and colorectal cancer where existing therapies are insufficient.

Investors · 2

FU

Fund+Leuven · $5.5M – $16.5M

NE

Newton BiocapitalBrussels